NCX 1015

Known as: NCX-1015, NCX1015 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2014
012320002014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
BACKGROUND The addition of a nitric oxide (NO)-releasing moiety to prednisolone was shown to enhance the anti-inflammatory… (More)
Is this relevant?
2004
2004
Daily administration of prednisolone, but not the derivative NCX-1015 (or prednisolone 21-[4'-nitrooxymethyl]benzoate), to rats… (More)
  • table 1
  • figure 1
  • table 2
  • figure 3
  • figure 2
Is this relevant?
2003
2003
It has recently emerged that posttranslational modification of proteins via nitration of tyrosine residues can alter their… (More)
  • figure 1
  • figure 2
  • table I
  • figure 3
  • figure 4
Is this relevant?
2003
2003
1. Derivatization of nonsteroidal anti-inflammatory drugs, such that they release nitric oxide (NO) in small amounts, has been… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Review
2003
Review
2003
Addition to the prednisolone structure of a chemical moiety (linker+nitric ester) that releases NO species yielded a novel… (More)
Is this relevant?
2002
2002
Here, we describe the improved antiarthritic properties of a nitric oxide-releasing derivative of prednisolone that includes a… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2002
2002
NCX-1015 is a nitric oxide (NO)-releasing derivative of prednisolone. In this study we show NCX-1015 protects mice against the S… (More)
Is this relevant?
2002
2002
 
Is this relevant?
2000
2000
1. Anti-inflammatory effects of a novel derivative of the glucocorticoid prednisolone were investigated. NCX-1015 (prednisolone… (More)
Is this relevant?